Senesco's technology shown to inhibit tumor development, increase longevity in mouse model

By Lisa Kerner

Erie, Pa., April 27 - Senesco Technologies, Inc. announced results of a study in which mice injected with tumor-forming B16F0 melanoma cancer cells were treated with Senesco's proprietary gene, eIF-5A (Factor 5A).

Treatment began after tumors formed in about nine days.

Two control groups of nine mice each received placebo treatments, while a test group of 10 mice received Factor 5A, intratumorally, every other day.

Senesco said the median survival was 25 days post-treatment for the Factor 5A-treated mice compared to seven days for the control mice.

Two of the Factor 5A- treated mice are still alive, with one mouse in apparent complete remission.

"These data build upon our previous preclinical cancer studies and provide more evidence for Factor 5A as an anti-cancer agent," executive vice president John Thompson said in a company news release.

Located in New Brunswick, N.J., Senesco develops technology that regulates the onset of cell death.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.